Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein
- PMID: 10993887
- DOI: 10.1074/jbc.M005605200
Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein
Abstract
Kallistatin is a serpin with a unique P1 Phe, which confers an excellent inhibitory specificity toward tissue kallikrein. In this study, we investigated the P3-P2-P1 residues (residues 386-388) of human kallistatin in determining inhibitory specificity toward human tissue kallikrein by site-directed mutagenesis and molecular modeling. Human kallistatin mutants with 19 different amino acid substitutions at each P1, P2, or P3 residue were created and purified to compare their kallikrein binding activity. Complex formation assay showed that P1 Arg, P1 Phe (wild type), P1 Lys, P1 Tyr, P1 Met, and P1 Leu display significant binding activity with tissue kallikrein among the P1 variants. Kinetic analysis showed the inhibitory activities of the P1 mutants toward tissue kallikrein in the order of P1 Arg > P1 Phe > P1 Lys >/= P1 Tyr > P1 Leu >/= P1 Met. P1 Phe displays a better selectivity for human tissue kallikrein than P1 Arg, since P1 Arg also inhibits several other serine proteinases. Heparin distinguishes the inhibitory specificity of kallistatin toward kallikrein versus chymotrypsin. For the P2 and P3 variants, the mutants with hydrophobic and bulky amino acids at P2 and basic amino acids at P3 display better binding activity with tissue kallikrein. The inhibitory activities of these mutants toward tissue kallikrein are in the order of P2 Phe (wild type) > P2 Leu > P2 Trp > P2 Met and P3 Arg > P3 Lys (wild type). Molecular modeling of the reactive center loop of kallistatin bound to the reactive crevice of tissue kallikrein indicated that the P2 residue required a long and bulky hydrophobic side chain to reach and fill the hydrophobic S2 cleft generated by Tyr(99) and Trp(219) of tissue kallikrein. Basic amino acids at P3 could stabilize complex formation by forming electrostatic interaction with Asp(98J) and hydrogen bond with Gln(174) of tissue kallikrein. Our results indicate that tissue kallikrein is a specific target proteinase for kallistatin.
Similar articles
-
A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein.J Biol Chem. 2000 Dec 22;275(51):40371-7. doi: 10.1074/jbc.M005691200. J Biol Chem. 2000. PMID: 10991942
-
Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis.Biochim Biophys Acta. 2000 Jun 15;1479(1-2):237-46. doi: 10.1016/s0167-4838(00)00044-3. Biochim Biophys Acta. 2000. PMID: 10862973
-
Identification of a major heparin-binding site in kallistatin.J Biol Chem. 2001 Jan 12;276(2):1276-84. doi: 10.1074/jbc.M005791200. J Biol Chem. 2001. PMID: 11016932
-
Tissue kallikrein inhibitors in mammals.Immunopharmacology. 1996 May;32(1-3):67-72. doi: 10.1016/0162-3109(96)00010-0. Immunopharmacology. 1996. PMID: 8796269 Review.
-
Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling.Biol Chem. 2001 Jan;382(1):15-21. doi: 10.1515/BC.2001.003. Biol Chem. 2001. PMID: 11258665 Review.
Cited by
-
93-kDa twin-domain serine protease inhibitor (Serpin) has a regulatory function on the beetle Toll proteolytic signaling cascade.J Biol Chem. 2011 Oct 7;286(40):35087-95. doi: 10.1074/jbc.M111.277343. Epub 2011 Aug 23. J Biol Chem. 2011. PMID: 21862574 Free PMC article.
-
Kallistatin suppresses cancer development by multi-factorial actions.Crit Rev Oncol Hematol. 2017 May;113:71-78. doi: 10.1016/j.critrevonc.2017.03.011. Epub 2017 Mar 14. Crit Rev Oncol Hematol. 2017. PMID: 28427524 Free PMC article. Review.
-
Heparin Blocks the Inhibition of Tissue Kallikrein 1 by Kallistatin through Electrostatic Repulsion.Biomolecules. 2020 May 28;10(6):828. doi: 10.3390/biom10060828. Biomolecules. 2020. PMID: 32481593 Free PMC article.
-
Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis.Exp Cell Res. 2016 Jan 15;340(2):305-14. doi: 10.1016/j.yexcr.2016.01.004. Epub 2016 Jan 11. Exp Cell Res. 2016. PMID: 26790955 Free PMC article.
-
Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6.Mol Cell Biochem. 2013 Jul;379(1-2):295-301. doi: 10.1007/s11010-013-1654-2. Epub 2013 May 12. Mol Cell Biochem. 2013. PMID: 23666756 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous